These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 19874553)

  • 1. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
    Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
    Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.
    Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M
    J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
    Berntsen A; Geertsen PF; Svane IM
    Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].
    Gao J; Chen M; Peng ML; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):198-201. PubMed ID: 15760555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK
    Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination.
    Burgdorf SK; Claesson MH; Nielsen HJ; Rosenberg J
    Acta Oncol; 2009; 48(8):1157-64. PubMed ID: 19863224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.
    Kim JH; Lee Y; Bae YS; Kim WS; Kim K; Im HY; Kang WK; Park K; Choi HY; Lee HM; Baek SY; Lee H; Doh H; Kim BM; Kim CY; Jeon C; Jung CW
    Clin Immunol; 2007 Dec; 125(3):257-67. PubMed ID: 17916447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
    Papewalis C; Fassnacht M; Willenberg HS; Domberg J; Fenk R; Rohr UP; Schinner S; Bornstein SR; Scherbaum WA; Schott M
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):215-22. PubMed ID: 16886963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
    Svane IM; Pedersen AE; Nikolajsen K; Zocca MB
    Vaccine; 2008 Aug; 26(36):4716-24. PubMed ID: 18616968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-tumor fusion vaccines for renal cell carcinoma.
    Avigan D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6347S-52S. PubMed ID: 15448029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine].
    Iinuma H; Okinaga K; Fukushima R; Inaba T; Iwasaki K; Arai T; Tamura J; Kumagai H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1640-2. PubMed ID: 15553669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
    Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
    Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
    Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.